AWE
SYRS

Avidian Wealth Enterprises’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Avidian Wealth Enterprises’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,600
Closed -$120K – 421
2021
Q1 		$120K Buy
+1,600
New +$166K 0.01% 357

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avidian Wealth Enterprises's SYRS Position: Q2 2021 in Review

Avidian Wealth Enterprises sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 1,600 shares — an estimated $120K sold.

Avidian Wealth Enterprises first reported a position in SYRS in Q1 2021 and held it in 1 quarter. The position peaked at $120K in Q1 2021. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • Avidian Wealth Enterprises reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Avidian Wealth Enterprises sold 1,600 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $120K.
  • Avidian Wealth Enterprises first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Avidian Wealth Enterprises's Syros Pharmaceuticals, Inc. Common Stock position peaked at $120K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Avidian Wealth Enterprises's 13F filing for Q2 2021, filed 9 Aug 2021.